Europe Approves Amgen's KRAS-Targeted Lung Cancer Therapy

The European Commission (EC) has granted conditional marketing authorization to Amgen Inc's AMGN Lumykras (sotorasib), a KRASG12C inhibitor, for non-small cell lung cancer (NSCLC).

  • The approval covers adult NSCLC patients with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy. 
  • In May 2021, Lumakras was the first KRASG12C inhibitor to receive regulatory approval with its approval in the U.S., under accelerated approval.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
  • The EC decision follows the recommendation for approval by the Committee for Medicinal Products for Human Use. It is based on the positive results from the Phase 2 CodeBreaK 100 clinical trial. 
  • Lumykras demonstrated an objective response rate of 37.1% and a median duration of response (DoR) of 11.1 months. 
  • Price Action: AMGN shares closed higher by 0.94% at $227.29 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsNon-Small Cell Lung Cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!